WallStreetZen

NYSE: GSK
Glaxosmithkline Plc Stock Forecast, Predictions & Price Target

Analyst price target for GSK

Based on 4 analysts offering 12 month price targets for Glaxosmithkline Plc.
Min Forecast
$41.50+8.19%
Avg Forecast
$47.63+24.15%
Max Forecast
$53.00+38.16%

Should I buy or sell GSK stock?

Buy
Strong Buy
3 analysts 42.86%
Buy
0 analysts 0%
Hold
4 analysts 57.14%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Forecast return on equity

Is GSK forecast to generate an efficient return?
Company
131.55%
Industry
75.54%
Market
61.82%
GSK's Return on Equity is forecast to be high in 4 years (131.55%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is GSK forecast to generate an efficient return on assets?
Company
18.83%
Industry
16.98%
Market
19.68%
GSK is forecast to generate higher Return on Assets (18.83%) than the US Drug Manufacturers - General industry average (16.98%)
Forecast

GSK earnings per share forecast

What is GSK's earnings per share in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$3.09+25.05%
Avg 2 year Forecast
$3.28+32.54%
Avg 3 year Forecast
$3.32+34.16%
GSK's earnings are forecast to grow at a rate of 10.77% per year, which is not exceptional
Forecast

GSK revenue forecast

What is GSK's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$45.9B+3.46%
Avg 2 year Forecast
$48.0B+8.15%
Avg 3 year Forecast
$49.3B+11.07%
GSK's revenue is forecast to grow at a rate of 3.69% per year, which is not exceptional
Forecast

GSK earnings growth forecast

How is GSK forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
10.77%
Industry
25.04%
Market
20.34%
GSK's earnings are forecast to grow slower (10.77% per year) than the US Drug Manufacturers - General industry average (25.04%)
Forecast
GSK's earnings are forecast to grow slower (10.77% per year) than the US market average (20.34%)
Forecast
GSK's earnings are forecast to grow faster (10.77% per year) than the risk-free savings rate (1.1%)
Forecast

GSK revenue growth forecast

How is GSK forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
3.69%
Industry
6.45%
Market
14.82%
GSK's revenues are forecast to grow slower (3.69% per year) than the US Drug Manufacturers - General industry average (6.45%)
Forecast
GSK's revenues are forecast to grow slower (3.69% per year) than the US market average (14.82%)
Forecast

Glaxosmithkline Stock Forecast FAQ

Is Glaxosmithkline Stock a good buy in 2019, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NYSE: GSK) stock is to Buy GSK stock.

Out of 7 analysts, 3 (42.86%) are recommending GSK as a Strong Buy, 0 (0%) are recommending GSK as a Buy, 4 (57.14%) are recommending GSK as a Hold, 0 (0%) are recommending GSK as a Sell, and 0 (0%) are recommending GSK as a Strong Sell.

What is GSK's Price Target?

According to 4 Wall Street analysts that have issued a 1 year GSK price target, the average GSK price target is $47.63, with the highest GSK stock price forecast at $53.00 and the lowest GSK stock price forecast at $41.50.

On average, Wall Street analysts predict that Glaxosmithkline's share price could reach $47.63 by Jan 20, 2022. The average Glaxosmithkline stock price prediction forecasts a potential upside of 24.15% from the current GSK share price of $38.36.

What is GSK's earnings growth forecast for 2021-2023?

(NYSE: GSK) Glaxosmithkline's forecast annual earnings growth rate of 10.77% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 25.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.34%.

Glaxosmithkline's earnings in 2019 is $6,111,842,105.On average, 6 Wall Street analysts forecast GSK's earnings for 2021 to be $16,621,318,958, with the lowest GSK earnings forecast at $15,706,877,462, and the highest GSK earnings forecast at $18,181,248,569. On average, 4 Wall Street analysts forecast GSK's earnings for 2022 to be $17,616,446,469, with the lowest GSK earnings forecast at $16,836,481,663, and the highest GSK earnings forecast at $18,880,527,360.

In 2023, GSK is forecast to generate $17,831,609,174 in earnings, with the lowest earnings forecast at $17,428,179,102 and the highest earnings forecast at $18,235,039,245.

What is GSK's revenue growth forecast for 2021-2023?

(NYSE: GSK) Glaxosmithkline's forecast annual revenue growth rate of 3.69% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.82%.

Glaxosmithkline's revenue in 2019 is $44,413,157,895.On average, 3 Wall Street analysts forecast GSK's revenue for 2021 to be $247,155,640,232,439, with the lowest GSK revenue forecast at $241,859,555,484,674, and the highest GSK revenue forecast at $251,154,154,013,536. On average, 3 Wall Street analysts forecast GSK's revenue for 2022 to be $258,379,726,455,233, with the lowest GSK revenue forecast at $251,328,866,129,964, and the highest GSK revenue forecast at $262,490,162,496,383.

In 2023, GSK is forecast to generate $265,354,919,436,235 in revenue, with the lowest revenue forecast at $259,447,492,894,867 and the highest revenue forecast at $271,262,345,977,602.

What is GSK's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: GSK) Glaxosmithkline's current Earnings Per Share (EPS) is $2.47. On average, analysts forecast that GSK's EPS will be $3.09 for 2021, with the lowest EPS forecast at $2.92, and the highest EPS forecast at $3.38. On average, analysts forecast that GSK's EPS will be $3.28 for 2022, with the lowest EPS forecast at $3.13, and the highest EPS forecast at $3.51. In 2023, GSK's EPS is forecast to hit $3.32 (min: $3.24, max: $3.39).

What is GSK's forecast return on equity (ROE) for 2021-2024?

(NYSE: GSK) forecast ROE is 131.55%, which is considered strong.

What is GSK's forecast return on assets (ROA) for 2021-2024?

(NYSE: GSK) forecast ROA is 18.83%, which is higher than the forecast US Drug Manufacturers - General industry average of 16.98%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics